Կոնակիոն

main_info

  • trade_name:
  • Կոնակիոն ՄՄ մանկական
  • dosage:
  • 2մգ/0,2մլ(5) ամպուլներ 0,2մլ և դեղաչափիչ սարք
  • pharmaceutical_form:
  • լուծույթ ներարկման/ներքին ընդունման
  • prescription_type:
  • Դեղատոմսով
  • medicine_domain:
  • Human
  • medicine_type:
  • Allopathic

documents

localization

  • country:
  • Կոնակիոն ՄՄ մանկական
    አርሜኒያ
  • language:
  • አማርኛ

other_info

status

  • source:
  • Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում - Armenia
  • last_update:
  • 31-05-2018

17-4-2019


Committee for Advanced Therapies (CAT): 23-25 January 2019, European Medicines Agency, London, UK, from 23/01/2019 to 25/01/2019

Committee for Advanced Therapies (CAT): 23-25 January 2019, European Medicines Agency, London, UK, from 23/01/2019 to 25/01/2019

Committee for Advanced Therapies (CAT): 23-25 January 2019, European Medicines Agency, London, UK, from 23/01/2019 to 25/01/2019

Europe - EMA - European Medicines Agency

17-4-2019


Committee for Advanced Therapies (CAT): 16-17 April 2019, European Medicines Agency, Amsterdam, the Netherlands, from 16/04/2019 to 17/04/2019

Committee for Advanced Therapies (CAT): 16-17 April 2019, European Medicines Agency, Amsterdam, the Netherlands, from 16/04/2019 to 17/04/2019

Committee for Advanced Therapies (CAT): 16-17 April 2019, European Medicines Agency, Amsterdam, the Netherlands, from 16/04/2019 to 17/04/2019

Europe - EMA - European Medicines Agency

17-4-2019


Committee for Advanced Therapies (CAT): 20-22 March 2019, European Medicines Agency, from 20/03/2019 to 22/03/2019

Committee for Advanced Therapies (CAT): 20-22 March 2019, European Medicines Agency, from 20/03/2019 to 22/03/2019

Committee for Advanced Therapies (CAT): 20-22 March 2019, European Medicines Agency, from 20/03/2019 to 22/03/2019

Europe - EMA - European Medicines Agency

12-4-2019

Fluoroquinolone antibiotics and risk of aortic aneurysm/dissection

Fluoroquinolone antibiotics and risk of aortic aneurysm/dissection

Medicines Safety Update - TGA investigating fluoroquinolone antibiotics and risk of aortic aneurysm/dissection

Therapeutic Goods Administration - Australia

10-4-2019

Report on suspected side effects reported for medicinal cannabis

Report on suspected side effects reported for medicinal cannabis

Dizziness, nausea and concentration problems are some of the suspected side effects that have been reported to the Danish Medicines Agency in the first year of the medicinal cannabis pilot programme.

Danish Medicines Agency

3-4-2019

FDA Posts Adverse Event Report Data for Animal Drugs and Devices Used in Animals to Increase Transparency

FDA Posts Adverse Event Report Data for Animal Drugs and Devices Used in Animals to Increase Transparency

In its continuing commitment to increase transparency, the U.S. Food and Drug Administration’s Center for Veterinary Medicine is announcing today the availability of data from over 30 years of adverse event reports related to animal drugs and devices used in animals.

FDA - U.S. Food and Drug Administration

3-4-2019


Paediatric Committee (PDCO): 26 February-1 March 2019, European Medicines Agency, from 26/02/2019 to 01/03/2019

Paediatric Committee (PDCO): 26 February-1 March 2019, European Medicines Agency, from 26/02/2019 to 01/03/2019

Paediatric Committee (PDCO): 26 February-1 March 2019, European Medicines Agency, from 26/02/2019 to 01/03/2019

Europe - EMA - European Medicines Agency

17-4-2019


Human medicines European public assessment report (EPAR): Ajovy, fremanezumab, Migraine Disorders, Date of authorisation: 28/03/2019, Status: Authorised

Human medicines European public assessment report (EPAR): Ajovy, fremanezumab, Migraine Disorders, Date of authorisation: 28/03/2019, Status: Authorised

Human medicines European public assessment report (EPAR): Ajovy, fremanezumab, Migraine Disorders, Date of authorisation: 28/03/2019, Status: Authorised

Europe - EMA - European Medicines Agency

17-4-2019


Human medicines European public assessment report (EPAR): Tobramycin PARI, tobramycin, Respiratory Tract Infections,Cystic Fibrosis, Date of authorisation: 18/02/2019, Status: Authorised

Human medicines European public assessment report (EPAR): Tobramycin PARI, tobramycin, Respiratory Tract Infections,Cystic Fibrosis, Date of authorisation: 18/02/2019, Status: Authorised

Human medicines European public assessment report (EPAR): Tobramycin PARI, tobramycin, Respiratory Tract Infections,Cystic Fibrosis, Date of authorisation: 18/02/2019, Status: Authorised

Europe - EMA - European Medicines Agency

17-4-2019


Human medicines European public assessment report (EPAR): Idacio, adalimumab, Arthritis, Rheumatoid,Arthritis, Juvenile Rheumatoid,Psoriasis,Arthritis, Psoriatic,Spondylitis, Ankylosing,Uveitis,Hidradenitis Suppurativa,Colitis, Ulcerative,Crohn Disease,

Human medicines European public assessment report (EPAR): Idacio, adalimumab, Arthritis, Rheumatoid,Arthritis, Juvenile Rheumatoid,Psoriasis,Arthritis, Psoriatic,Spondylitis, Ankylosing,Uveitis,Hidradenitis Suppurativa,Colitis, Ulcerative,Crohn Disease,

Human medicines European public assessment report (EPAR): Idacio, adalimumab, Arthritis, Rheumatoid,Arthritis, Juvenile Rheumatoid,Psoriasis,Arthritis, Psoriatic,Spondylitis, Ankylosing,Uveitis,Hidradenitis Suppurativa,Colitis, Ulcerative,Crohn Disease, Date of authorisation: 02/04/2019, Status: Authorised

Europe - EMA - European Medicines Agency

17-4-2019

ACCM meeting statement, Meeting 21, 28 March 2019

ACCM meeting statement, Meeting 21, 28 March 2019

Advisory Committee on Complementary Medicines meeting statement for 28 March 2019

Therapeutic Goods Administration - Australia

15-4-2019

Irbesartan Teva (Teva B.V.)

Irbesartan Teva (Teva B.V.)

Irbesartan Teva (Active substance: Irbesartan) - Referral - Commission Decision (2019)2975 of Mon, 15 Apr 2019 European Medicines Agency (EMA) procedure number: EMEA/H/A-31/1471/C/1093/32

Europe -DG Health and Food Safety

15-4-2019

Versican Plus Pi/L4 (Zoetis Belgium S.A.)

Versican Plus Pi/L4 (Zoetis Belgium S.A.)

Versican Plus Pi/L4 (Active substance: Canine parainfluenza virus vaccine (live) and canine leptospirosis vaccine (inactivated)) - Centralised - Renewal - Commission Decision (2019)2964 of Mon, 15 Apr 2019 European Medicines Agency (EMA) procedure number: EMEA/V/C/3683/R/11

Europe -DG Health and Food Safety

12-4-2019


Human medicines highlights - April 2019

Human medicines highlights - April 2019

Human medicines highlights - April 2019

Europe - EMA - European Medicines Agency

12-4-2019

capecitabine

capecitabine

capecitabine (Active substance: capecitabine) - Centralised - Art 28 - (PSUR - Commission Decision (2019)2988 of Fri, 12 Apr 2019 European Medicines Agency (EMA) procedure number: EMEA/H/C/PSUSA/531/201804

Europe -DG Health and Food Safety

12-4-2019

EU/3/18/2038 (PPD Bulgaria EOOD)

EU/3/18/2038 (PPD Bulgaria EOOD)

EU/3/18/2038 (Active substance: Palovarotene) - Transfer of orphan designation - Commission Decision (2019)2940 of Fri, 12 Apr 2019 European Medicines Agency (EMA) procedure number: EMA/OD/0000005020

Europe -DG Health and Food Safety

12-4-2019

EU/3/16/1665 (Diamond ROC EOOD)

EU/3/16/1665 (Diamond ROC EOOD)

EU/3/16/1665 (Active substance: Recombinant adeno-associated viral vector containing the human RPGR gene) - Transfer of orphan designation - Commission Decision (2019)2934 of Fri, 12 Apr 2019 European Medicines Agency (EMA) procedure number: EMA/OD/0000005876

Europe -DG Health and Food Safety

12-4-2019

EU/3/15/1556 (Diamond ROC EOOD)

EU/3/15/1556 (Diamond ROC EOOD)

EU/3/15/1556 (Active substance: Recombinant adeno-associated viral vector containing human CNGA3 gene) - Transfer of orphan designation - Commission Decision (2019)2933 of Fri, 12 Apr 2019 European Medicines Agency (EMA) procedure number: EMA/OD/0000005873

Europe -DG Health and Food Safety

12-4-2019

EU/3/13/1107 (Diamond ROC EOOD)

EU/3/13/1107 (Diamond ROC EOOD)

EU/3/13/1107 (Active substance: Recombinant adeno-associated viral vector containing the human retinoschisin gene) - Transfer of orphan designation - Commission Decision (2019)2932 of Fri, 12 Apr 2019 European Medicines Agency (EMA) procedure number: EMA/OD/0000005875

Europe -DG Health and Food Safety

12-4-2019

EU/3/13/1099 (Diamond ROC EOOD)

EU/3/13/1099 (Diamond ROC EOOD)

EU/3/13/1099 (Active substance: Recombinant adeno-associated viral vector containing the human CNGB3 gene) - Transfer of orphan designation - Commission Decision (2019)2931 of Fri, 12 Apr 2019 European Medicines Agency (EMA) procedure number: EMA/OD/0000005874

Europe -DG Health and Food Safety

12-4-2019

EU/3/07/440 (Diamond ROC EOOD)

EU/3/07/440 (Diamond ROC EOOD)

EU/3/07/440 (Active substance: Recombinant adeno-associated viral vector containing human alpha-1 antitrypsin gene) - Transfer of orphan designation - Commission Decision (2019)2930 of Fri, 12 Apr 2019 European Medicines Agency (EMA) procedure number: EMA/OD/0000005871

Europe -DG Health and Food Safety

12-4-2019

EU/3/18/2124 (IntraBio Ireland Ltd)

EU/3/18/2124 (IntraBio Ireland Ltd)

EU/3/18/2124 (Active substance: Acetylleucine) - Transfer of orphan designation - Commission Decision (2019)2939 of Fri, 12 Apr 2019 European Medicines Agency (EMA) procedure number: EMA/OD/0000005404

Europe -DG Health and Food Safety

12-4-2019

EU/3/18/2059 (IntraBio Ireland Ltd)

EU/3/18/2059 (IntraBio Ireland Ltd)

EU/3/18/2059 (Active substance: Acetylleucine) - Transfer of orphan designation - Commission Decision (2019)2938 of Fri, 12 Apr 2019 European Medicines Agency (EMA) procedure number: EMA/OD/0000005399

Europe -DG Health and Food Safety

12-4-2019

EU/3/17/1949 (IntraBio Ireland Ltd)

EU/3/17/1949 (IntraBio Ireland Ltd)

EU/3/17/1949 (Active substance: Acetylleucine) - Transfer of orphan designation - Commission Decision (2019)2936 of Fri, 12 Apr 2019 European Medicines Agency (EMA) procedure number: EMA/OD/0000005385

Europe -DG Health and Food Safety

12-4-2019

EU/3/17/1878 (IntraBio Ireland Ltd)

EU/3/17/1878 (IntraBio Ireland Ltd)

EU/3/17/1878 (Active substance: Ursodeoxycholic acid) - Transfer of orphan designation - Commission Decision (2019)2937 of Fri, 12 Apr 2019 European Medicines Agency (EMA) procedure number: EMA/OD/0000005394

Europe -DG Health and Food Safety

12-4-2019

EU/3/17/1848 (IntraBio Ireland Ltd)

EU/3/17/1848 (IntraBio Ireland Ltd)

EU/3/17/1848 (Active substance: Acetylleucine) - Transfer of orphan designation - Commission Decision (2019)2935 of Fri, 12 Apr 2019 European Medicines Agency (EMA) procedure number: EMA/OD/0000005357

Europe -DG Health and Food Safety

12-4-2019

EU/3/18/1977 (GW Pharma (International) B.V)

EU/3/18/1977 (GW Pharma (International) B.V)

EU/3/18/1977 (Active substance: Cannabidivarin) - Transfer of orphan designation - Commission Decision (2019)2929 of Fri, 12 Apr 2019 European Medicines Agency (EMA) procedure number: EMA/OD/0000004768

Europe -DG Health and Food Safety

12-4-2019

EU/3/17/1959 (GW Pharma (International) B.V)

EU/3/17/1959 (GW Pharma (International) B.V)

EU/3/17/1959 (Active substance: Cannabidiol) - Transfer of orphan designation - Commission Decision (2019)2925 of Fri, 12 Apr 2019 European Medicines Agency (EMA) procedure number: EMA/OD/0000004767

Europe -DG Health and Food Safety

12-4-2019

EU/3/17/1921 (GW Pharma (International) B.V)

EU/3/17/1921 (GW Pharma (International) B.V)

EU/3/17/1921 (Active substance: Cannabidivarin) - Transfer of orphan designation - Commission Decision (2019)2928 of Fri, 12 Apr 2019 European Medicines Agency (EMA) procedure number: EMA/OD/0000004766

Europe -DG Health and Food Safety

12-4-2019

EU/3/17/1920 (GW Pharma (International) B.V)

EU/3/17/1920 (GW Pharma (International) B.V)

EU/3/17/1920 (Active substance: Cannabidiol) - Transfer of orphan designation - Commission Decision (2019)2927 of Fri, 12 Apr 2019 European Medicines Agency (EMA) procedure number: EMA/OD/0000004765

Europe -DG Health and Food Safety

12-4-2019

EU/3/17/1855 (GW Pharma (International) B.V)

EU/3/17/1855 (GW Pharma (International) B.V)

EU/3/17/1855 (Active substance: Cannabidiol) - Transfer of orphan designation - Commission Decision (2019)2926 of Fri, 12 Apr 2019 European Medicines Agency (EMA) procedure number: EMA/OD/0000004607

Europe -DG Health and Food Safety

12-4-2019

EU/3/16/1621 (GW Pharma (International) B.V)

EU/3/16/1621 (GW Pharma (International) B.V)

EU/3/16/1621 (Active substance: Delta-9-tetrahydrocannabinol and cannabidiol from extracts of the Cannabis sativa L. plant) - Transfer of orphan designation - Commission Decision (2019)2924 of Fri, 12 Apr 2019 European Medicines Agency (EMA) procedure number: EMA/OD/0000004763

Europe -DG Health and Food Safety

12-4-2019

EU/3/14/1339 (GW Pharma (International) B.V)

EU/3/14/1339 (GW Pharma (International) B.V)

EU/3/14/1339 (Active substance: Cannabidiol) - Transfer of orphan designation - Commission Decision (2019)2923 of Fri, 12 Apr 2019 European Medicines Agency (EMA) procedure number: EMA/OD/0000004708

Europe -DG Health and Food Safety

12-4-2019

EU/3/18/2126 (JVM Europe B.V.)

EU/3/18/2126 (JVM Europe B.V.)

EU/3/18/2126 (Active substance: Human glucagon-like peptide-2 analogue linked to a human immunoglobulin Fc fragment) - Transfer of orphan designation - Commission Decision (2019)2922 of Fri, 12 Apr 2019 European Medicines Agency (EMA) procedure number: EMA/OD/0000005194

Europe -DG Health and Food Safety

12-4-2019

EU/3/18/2035 (JVM Europe B.V.)

EU/3/18/2035 (JVM Europe B.V.)

EU/3/18/2035 (Active substance: Efpegsomatropin) - Transfer of orphan designation - Commission Decision (2019)2921 of Fri, 12 Apr 2019 European Medicines Agency (EMA) procedure number: EMA/OD/0000005050

Europe -DG Health and Food Safety

12-4-2019

EU/3/18/2022 (JVM Europe B.V.)

EU/3/18/2022 (JVM Europe B.V.)

EU/3/18/2022 (Active substance: Glucagon analogue linked to a human immunoglobulin Fc fragment) - Transfer of orphan designation - Commission Decision 2920 of Fri, 12 Apr 2019 European Medicines Agency (EMA) procedure number: EMA/OD/0000005277

Europe -DG Health and Food Safety

12-4-2019


Use of multiple sclerosis medicine Lemtrada restricted while EMA review is ongoing

Use of multiple sclerosis medicine Lemtrada restricted while EMA review is ongoing

Use of multiple sclerosis medicine Lemtrada restricted while EMA review is ongoing

Europe - EMA - European Medicines Agency

12-4-2019

Can I import a medicine for personal use?

Can I import a medicine for personal use?

Provided all approriate rules are followed, many medicines can be imported for personal use under the Personal Importation Scheme.

Therapeutic Goods Administration - Australia

10-4-2019

Versican Plus DHPPi/L4R (Zoetis Belgium S.A.)

Versican Plus DHPPi/L4R (Zoetis Belgium S.A.)

Versican Plus DHPPi/L4R (Active substance: Canine distemper, canine adenovirus, canine parvovirus and canine parainfluenza virus vaccine (live) and canine leptospirosis and rabies vaccine (inactivated)) - Centralised - Renewal - Commission Decision (2019)2850 of Wed, 10 Apr 2019 European Medicines Agency (EMA) procedure number: EMEA/V/C/2759/R/14

Europe -DG Health and Food Safety

10-4-2019

Versican Plus L4 (Zoetis Belgium S.A.)

Versican Plus L4 (Zoetis Belgium S.A.)

Versican Plus L4 (Active substance: Canine leptospirosis vaccine (inactivated)) - Centralised - Renewal - Commission Decision (2019)2848 of Wed, 10 Apr 2019 European Medicines Agency (EMA) procedure number: EMEA/V/C/3680/R/07

Europe -DG Health and Food Safety

10-4-2019

Versican Plus DHPPi/L4 (Zoetis Belgium S.A.)

Versican Plus DHPPi/L4 (Zoetis Belgium S.A.)

Versican Plus DHPPi/L4 (Active substance: Canine distemper, canine adenovirus, canine parvovirus and canine parainfluenza virus vaccine (live) and canine leptospirosis vaccine (inactivated)) - Centralised - Renewal - Commission Decision (2019)2849 of Wed, 10 Apr 2019 European Medicines Agency (EMA) procedure number: EMEA/V/C/3678/R/13

Europe -DG Health and Food Safety

10-4-2019

M-M-RVAXPRO (MSD VACCINS)

M-M-RVAXPRO (MSD VACCINS)

M-M-RVAXPRO (Active substance: Measles, Mumps and Rubella Vaccine (Live)) - PSUSA - Modification - Commission Decision (2019)2812 of Wed, 10 Apr 2019 European Medicines Agency (EMA) procedure number: EMEA/H/C/PSUSA/00001937/201805

Europe -DG Health and Food Safety

10-4-2019

DuoResp Spiromax (Teva Pharma B.V.)

DuoResp Spiromax (Teva Pharma B.V.)

DuoResp Spiromax (Active substance: budesonide / formoterol) - Centralised - Renewal - Commission Decision (2019)2810 of Wed, 10 Apr 2019 European Medicines Agency (EMA) procedure number: EMEA/H/C/002348/R/0027

Europe -DG Health and Food Safety

10-4-2019

BiResp Spiromax (Teva Pharma B.V.)

BiResp Spiromax (Teva Pharma B.V.)

BiResp Spiromax (Active substance: budesonide / formoterol) - Centralised - Renewal - Commission Decision (2019)2811 of Wed, 10 Apr 2019 European Medicines Agency (EMA) procedure number: EMEA/H/C/003890/R/0027

Europe -DG Health and Food Safety

10-4-2019

Capecitabine medac (medac Gesellschaft fUr klinische SpezialprAparate mbH)

Capecitabine medac (medac Gesellschaft fUr klinische SpezialprAparate mbH)

Capecitabine medac (Active substance: capecitabine) - PSUSA - Modification - Commission Decision (2019)2817 of Wed, 10 Apr 2019 European Medicines Agency (EMA) procedure number: EMEA/H/C/PSUSA/00000531/201804

Europe -DG Health and Food Safety

10-4-2019

Don’t forget your toothbrush … or your medicines

Don’t forget your toothbrush … or your medicines

Heading overseas? Read our tips for travelling with medicines before you go

Therapeutic Goods Administration - Australia

9-4-2019


European Directorate for the Quality of Medicines and HealthCare (EDQM) of the Council of Europe

European Directorate for the Quality of Medicines and HealthCare (EDQM) of the Council of Europe

European Directorate for the Quality of Medicines and HealthCare (EDQM) of the Council of Europe

Europe - EMA - European Medicines Agency

5-4-2019

ACSS public statement, 29-30 October 2018

ACSS public statement, 29-30 October 2018

The Public Statement for the Generic Medicines Working Group face-to-face meeting in Canberra, October 2018

Therapeutic Goods Administration - Australia

4-4-2019

Deltyba (Otsuka Novel Products GmbH)

Deltyba (Otsuka Novel Products GmbH)

Deltyba (Active substance: delamanid) - Centralised - Annual renewal - Commission Decision (2019)2687 of Thu, 04 Apr 2019 European Medicines Agency (EMA) procedure number: EMEA/H/C/002552/R/0033

Europe -DG Health and Food Safety

4-4-2019

Kromeya (Fresenius Kabi Deutschland GmbH)

Kromeya (Fresenius Kabi Deutschland GmbH)

Kromeya (Active substance: adalimumab) - Centralised - Authorisation - Commission Decision (2019)2688 of Thu, 04 Apr 2019 European Medicines Agency (EMA) procedure number: EMEA/H/C/005158/0000

Europe -DG Health and Food Safety

4-4-2019

Betmiga (Astellas Pharma Europe B.V.)

Betmiga (Astellas Pharma Europe B.V.)

Betmiga (Active substance: mirabegron) - PSUSA - Modification - Commission Decision (2019)2689 of Thu, 04 Apr 2019 European Medicines Agency (EMA) procedure number: EMEA/H/C/PSUSA/00010031/201806

Europe -DG Health and Food Safety

4-4-2019

Vizimpro (Pfizer Europe MA EEIG)

Vizimpro (Pfizer Europe MA EEIG)

Vizimpro (Active substance: dacomitinib) - Centralised - Authorisation - Commission Decision (2019)2693 of Thu, 04 Apr 2019 European Medicines Agency (EMA) procedure number: EMEA/H/C/4779

Europe -DG Health and Food Safety

4-4-2019

Idacio (Fresenius Kabi Deutschland GmbH)

Idacio (Fresenius Kabi Deutschland GmbH)

Idacio (Active substance: adalimumab) - Centralised - Authorisation - Commission Decision C(2019) 2699 of Thu, 04 Apr 2019 European Medicines Agency (EMA) procedure number: EMEA/H/C/004475/0000

Europe -DG Health and Food Safety

4-4-2019

Sylvant (Janssen-Cilag International NV)

Sylvant (Janssen-Cilag International NV)

Sylvant (Active substance: siltuximab) - Centralised - Renewal - Commission Decision (2019)2713 of Thu, 04 Apr 2019 European Medicines Agency (EMA) procedure number: EMEA/H/C/3708/R/0029

Europe -DG Health and Food Safety

4-4-2019

Gazyvaro (Roche Registration GmbH)

Gazyvaro (Roche Registration GmbH)

Gazyvaro (Active substance: obinutuzumab) - Centralised - Renewal - Commission Decision (2019)2712 of Thu, 04 Apr 2019 European Medicines Agency (EMA) procedure number: EMEA/H/C/2799/R/0031

Europe -DG Health and Food Safety

3-4-2019

EU/3/17/1842 (EUDRAC GmbH)

EU/3/17/1842 (EUDRAC GmbH)

EU/3/17/1842 (Active substance: Recombinant human club cell 10 KDa protein) - Transfer of orphan designation - Commission Decision (2019)2668 of Wed, 03 Apr 2019 European Medicines Agency (EMA) procedure number: EMA/OD/0000004449

Europe -DG Health and Food Safety

3-4-2019

EU/3/19/2150 (Real Regulatory Limited)

EU/3/19/2150 (Real Regulatory Limited)

EU/3/19/2150 (Active substance: Codon-optimised human cystic fibrosis transmembrane conductance regulator messenger ribonucleic acid complexed with lipid-based nanoparticles) - Orphan designation - Commission Decision (2019)2666 of Wed, 03 Apr 2019 European Medicines Agency (EMA) procedure number: EMA/OD/0000002333

Europe -DG Health and Food Safety

3-4-2019

EU/3/19/2146 (Taiho Pharma Europe Limited)

EU/3/19/2146 (Taiho Pharma Europe Limited)

EU/3/19/2146 (Active substance: 1-[(3S)-3-{4-amino-3-[(3,5-dimethoxyphenyl)ethynyl]-1H-pyrazolo[3,4-d]pyrimidin-1-yl}pyrrolidin-1-yl]-2-propen-1-one) - Orphan designation - Commission Decision (2019)2662 of Wed, 03 Apr 2019 European Medicines Agency (EMA) procedure number: EMA/OD/0000002457

Europe -DG Health and Food Safety

3-4-2019

EU/3/16/1628 (New B Innovation Biopharmaceutical (Ireland) Limited)

EU/3/16/1628 (New B Innovation Biopharmaceutical (Ireland) Limited)

EU/3/16/1628 (Active substance: Diaspirin cross-linked haemoglobin) - Transfer of orphan designation - Commission Decision (2019)2673 of Wed, 03 Apr 2019 European Medicines Agency (EMA) procedure number: EMA/OD/0000003473

Europe -DG Health and Food Safety

3-4-2019

EU/3/14/1378 (New B Innovation Biopharmaceutical (Ireland) Limited)

EU/3/14/1378 (New B Innovation Biopharmaceutical (Ireland) Limited)

EU/3/14/1378 (Active substance: Diaspirin cross-linked haemoglobin) - Transfer of orphan designation - Commission Decision (2019)2672 of Wed, 03 Apr 2019 European Medicines Agency (EMA) procedure number: EMA/OD/0000003420

Europe -DG Health and Food Safety

3-4-2019

EU/3/15/1520 (GW Pharma (International) B.V)

EU/3/15/1520 (GW Pharma (International) B.V)

EU/3/15/1520 (Active substance: Cannabidiol) - Transfer of orphan designation - Commission Decision (2019)2674 of Wed, 03 Apr 2019 European Medicines Agency (EMA) procedure number: EMA/OD/0000004600

Europe -DG Health and Food Safety